Relay Therapeutics
NASDAQ · RLAY·Cambridge, MA·Small-cap·Phase 3
Clinical-stage precision medicines biotech using protein motion-based drug discovery (Dynamo platform). Lead asset RLY-2608 is a pan-mutant PI3Kα inhibitor in Phase 3 for HR+/HER2- breast cancer (ReDiscover-2 trial).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Relay Therapeutics April 2026 Corporate Presentation | Corporate overview | April 15, 2026 | 74 |